Physiomics (AIM: PYC) has been awarded a new contract by its long-standing client, Numab Therapeutics, to develop a mechanistic pharmacokinetic-pharmacodynamic (PK/PD) modelling framework to support proof-of-concept work for a new oncology programme.
Numab Therapeutics is a biopharmaceutical company focused on next-generation multispecific antibody-based therapeutics for inflammation and oncology. Under the contract, Physiomics will apply quantitative modelling approaches to interpret emerging data, optimise experimental design and development strategy, and inform key go/no-go decisions across the programme.
The project is expected to commence this month and be completed in the third quarter of 2026.
Dr Peter Sargent, CEO of Physiomics, said: “We are thrilled to extend our collaboration with Numab Therapeutics to provide insights that can support robust proof-of-concept decision-making for this early oncology programme.”
The new deal comes as Physiomics prepares to fight a requisitioned general meeting that seeks to remove and replace the current management.
The vote will take place later in April.